Begin main content

ixekizumab

Last Updated: October 23, 2019
Result type: Reports
Project Number: SR0630-000
Product Line: Common Drug Review

Generic Name: ixekizumab

Brand Name: Taltz

Manufacturer: Eli Lilly Canada Inc.

Indications: Ankylosing spondylitis

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.

Submission Type: New Indication

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule B

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedAugust 01, 2019
Patient group input closedSeptember 23, 2019
Clarification:

- Patient input submission received from Arthritis Consumer Experts, Canadian Arthritis Patient Alliance and Canadian Spondylitis Association

Patient input summary sent for review to patient input groupsOctober 15, 2019
Patient group comments on input summary closedOctober 22, 2019
Clarification:

- Patient input summary feedback received

Submission receivedSeptember 20, 2019
Submission accepted for reviewOctober 08, 2019
Clarification:

- Submission was not accepted for review on 4 Oct 2019

- Revised category 1 requirements received on 7 Oct 2019

Review initiatedOctober 09, 2019
Draft CADTH review report(s) sent to sponsorDecember 23, 2019
Comments from sponsor on draft CADTH review report(s) receivedJanuary 09, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsorFebruary 06, 2020
Canadian Drug Expert Committee (CDEC) meetingFebruary 19, 2020
CDEC recommendation sent to sponsor and drug plansMarch 02, 2020
To
March 04, 2020